Latest Oncology News

Brain Imaging Plus Virtual Reality Shows Promise for Effectively Managing Cancer Pain

April 3rd 2025

Roswell Park Comprehensive Cancer Center

Roswell Park-led study takes a significant step toward relief without opioid.

Avutometinib/Defactinib Combo Shows Potential in Recurrent Mesonephric Gynecologic Cancer

April 3rd 2025

Jax DiEugenio

Rachel N. Grisham, MD, discusses the preliminary results of avutometinib plus defactinib in mesonephric and mesonephric-like cancers.

Survey Identifies Factors Most Important to Fellows When Selecting a Career Path

April 3rd 2025

Kyle Doherty

A cross-sectional study reveals insights on factors hematology and oncology fellows weigh when selecting a career path after fellowship.

ADC-Based Combinations Gain Momentum in Bladder Cancer Management: With Chandler Park, MD; and Vadim Koshkin, MD

April 3rd 2025

Chandler Park, MD, MSc, FACP

Drs Park and Koshkin discuss the benefits of enfortumab vedotin in bladder cancer and the potential for more ADCs to join the treatment paradigm.

Updated ALLELE Data Confirm Clinical Benefit of Tabelecleucel in EBV+ Post-Transplant Lymphoproliferative Disease

April 2nd 2025

Courtney Flaherty

Tabelecleucel generated high response rates and favorable OS in patients with EBV-positive PTLD who had progressed on prior standard-of-care approaches.

Latest Oncology Videos

Selecting Candidates for CAR T-Cell Therapy in R/R DLBCL: Patient Characteristics, Eligibility, and Timing Considerations

Continued Advances and Treatment Sequencing for HR+/HER2– Breast Cancer

Dr Moertel on the Importance of Managing MEK Inhibitor–Associated Toxicites in NF1-Associated PN

Expert Insights for Approaching Patient Counseling for CAR T-Cell Therapy in R/R DLBCL

Current Treatment Approaches and Challenges in Platinum-Resistant Ovarian Cancer

Dr Vose on the Optimal Role for Epcoritamab in Relapsed/Refractory LBCL

Dr Herzberg on Notable Ongoing Research in KRAS-Mutated NSCLC

Dr Randall on Survey Results for Frozen Margin Sampling in Soft Tissue Sarcoma Resection

Dr Carles Galceran on the Safety of Darolutamide with ADT and Docetaxel in Older Patients With mHSPC

Dr Merseburger on Real-World Avelumab/Axitinib Discontinuations in Advanced RCC

Dr Kopetz on the Safety of Encorafenib Plus Cetuximab in BRAF V600E+ CRC

Guiding Patients Through CAR T: Key Discussion Points

CAR-T in Third-Line-Plus LBCL: Treatment Sequencing and Patient Selection

Dr Morris on the FDA's Expanded Approval of Lutetium Lu 177 Vipivotide Tetraxetan for PSMA+ mCRPC

Dr Chan on the Prevalence of Neuroendocrine Tumors in Young-Adult Patients

Key Takeaways From ASCO GI 2025: Exciting Updates on BTC

Dr Dorff on the Safety of Lutetium Lu 177 Vipivotide Tetraxetan in mCRPC With Renal Impairment

Dr Gupta on Considerations for Frontline Treatment Selection in HR+/HER2-Negative Breast Cancer

Dr Kaiser on Advances With Minimally Invasive Surgery in CRC

Dr Mateos on Long-Term OS Data From the Phase 3 CARTITUDE-4 Study of Cilta-Cel in Lenalidomide-Refractory Multiple Myeloma

Dr Politikos on the Immune Reconstitution Profiles of Orca-T and CD34 Allograft Recipients in Hematologic Malignancies

Dr Lee on Responses With Nivolumab in Resectable dMMR Endometrial Cancer

Dr Olawaiye on the Potential Role of Afuresertib Plus Paclitaxel in pAKT-Expressing Platinum-Resistant Ovarian Cancer

All Oncology News

Pacritinib Elicits Early Responses in Multi-Refractory Chronic Graft-Vs-Host Disease

April 2nd 2025

Kristi Rosa

Pacritinib was active and safe in patients with multi-refractory chronic graft-vs-host disease.

OncLive’s FDA Approval Report: The Regulatory Rundown for March 2025

April 2nd 2025

Kristi Rosa

Here is your snapshot for all therapeutic options that were approved by the FDA in March 2025 spanning tumor types.

Axi-Cel Is Associated With Higher ORR, Increased CRS/ICANS vs Tisa-cel in Older Patients With R/R DLBCL

April 2nd 2025

Jax DiEugenio

Axi-cel led to higher response rates but increased toxicity vs tisa-cel in older patients with relapsed/refractory DLBCL.

Axatilimab After Second-Line Therapy Generates ORR Benefit in Steroid-Refractory cGVHD

April 2nd 2025

Ashley Chan

A consistent ORR was shown with axatilimab after second-line therapy, regardless of prior lines of therapy, in patients with steroid-refractory cGVHD.

ICANS, Corticosteroid Use Identified As Risk Factors for NRM-Associated Infections After Axi-Cel Infusion in R/R NHL

April 2nd 2025

Ashling Wahner

Infections occur early after CAR T-cell therapy administration in patients with relapsed/refractory NHL.

Brexu-Cel Demonstrates Efficacy, Safety in Older Patients with R/R Mantle Cell Lymphoma

April 2nd 2025

Chris Ryan

Brexu-cel demonstrated clinical activity and safety in patients over 70 years of age with relapsed/refractory mantle cell lymphoma.

Orca-T Boosts cGVHD-Free Survival vs Allo-HSCT in Advanced Hematologic Malignancies

April 2nd 2025

Chris Ryan

Orca-T improved moderate-to-severe cGVHD–free survival vs conventional allogenic transplant in advanced hematologic malignancies.

Denosumab Biosimilars Earn Positive CHMP Opinion for Osteoporosis and Cancer-Related Bone Disease

April 2nd 2025

Courtney Flaherty

The EMA’s CHMP has issued a positive opinion for the denosumab biosimilars Osvyrti and Jubereq for the same indications as the reference products.

Silmitasertib Drives Disease Control in Advanced Basal Cell Carcinoma

April 2nd 2025

Chris Ryan

Silmitasertib generated disease control in patients with locally advanced or metastatic basal cell carcinoma.

Two MD Anderson Researchers Elected AAAS Fellows

April 2nd 2025

MD Anderson Cancer Center

Lung cancer clinician and prevention expert recognized for their achievements in advancing cancer care and research.

Revisit Every OncLive On Air Episode From March 2025

April 2nd 2025

Ashling Wahner

Read a recap of the episodes of OncLive On Air that aired in March 2025.

D-VRd Plus Daratumumab/Lenalidomide Maintenance Yields Favorable PFS Outcomes in High-Risk Myeloma

April 1st 2025

Ashling Wahner

D-VRd with daratumumab/lenalidomide maintenance led to sustained PFS and MRD negativity across high-risk subgroups of newly diagnosed multiple myeloma.

Cilta-Cel Significantly Boosts MRD Negativity Rates in Lenalidomide-Refractory Myeloma

April 1st 2025

Ashley Chan

Cilta-cel improved rates of MRD negativity and 30-month PFS vs SOC in patients with lenalidomide-refractory multiple myeloma with MRD negativity.

MDC-CAR-BCMA001 Shows Efficacy, Safety as Compassionate Use in R/R Multiple Myeloma and AL Amyloidosis

April 1st 2025

Courtney Flaherty

MDC-CAR-BCMA001 may be a suitable construct for the treatment of BCMA-pretreated patients with triple-class refractory multiple myeloma or AL amyloidosis.

Cilta-Cel Significantly Prolongs OS Vs SOC in Lenalidomide-Refractory Multiple Myeloma

April 1st 2025

Kristi Rosa

Ciltacabtagene autoleucel is the first CAR T-cell therapy to show significant OS benefit in multiple myeloma.

See All News